NCT04579224 2026-03-19
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT06133517 2026-03-16
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Fundación para el Progreso de la Oncología en Cantabria
Phase 2 Active not recruiting
NCT06028932 2026-03-05
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
Phase 2 Active not recruiting
NCT06100874 2026-02-24
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting